{"id":"NCT01709747","sponsor":"Piramal Critical Care, Ltd.","briefTitle":"Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration","officialTitle":"A Phase 3, Open-Label, Single-Arm Study To Assess The Safety Of Hydromorphone Hydrochloride Delivered By Intrathecal Administration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2018-02","completion":"2018-02","firstPosted":"2012-10-18","resultsPosted":"2021-08-25","lastUpdate":"2021-08-25"},"enrollment":364,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain"],"interventions":[{"type":"DRUG","name":"Hydromorphone Hydrochloride","otherNames":["Hydromorphone","Opioid"]},{"type":"DEVICE","name":"Programmable Implantable pump","otherNames":[]}],"arms":[{"label":"Hydromorphone Hydrochloride","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of hydromorphone hydrochloride administered by intrathecal delivery.","primaryOutcome":{"measure":"Granulomas","timeFrame":"12 months","effectByArm":[{"arm":"Hydromorphone Hydrochloride","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":364},"commonTop":["Back Pain","Nausea","Pain In Extremity","Vomiting","Arthralgia"]}}